艾普奈珠单抗(Eptinezumab-JJMR) - 药物靶点：CGRP_在研适应症：偏头痛，继发性头痛症，丛集性头痛_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

Eptinezumab、ALD-403、LU AG09221

+ [1]

靶点

CGRP

作用机制

CGRP拮抗剂(降钙素基因相关肽拮抗剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

H. Lundbeck A/SLundbeck Canada Inc.

Lundbeck Seattle BioPharmaceuticals, Inc.

+ [1]

非在研机构-

最高研发阶段批准上市

首次获批日期

美国 (2020-02-21),

偏头痛

最高研发阶段(中国)临床3期

特殊审评-

登录后查看首次获批时间轴

序列信息

Sequence Code 156338L

来源: *****

Sequence Code 201708H

来源: *****

关联

44

项与艾普奈珠单抗相关的临床试验

NCT06428838 / Not yet recruiting临床3期

Eptinezumab as an Adjunct to Standard of Care for MIGRANE in an Acute EmeRgency Context (Migraine ERase Study)

The purpose of the study is to investigate how a medication called eptinezumab (Vyepti) given to patients in the Emergency Department (ED) might help prevent migraines from happening again. The results of this study may help inform better ways to manage patients with migraines in the ED.
Eptinezumab is currently approved by Health Canada for the preventive treatment of migraine, but its short-term effectiveness in the ED context is unknown. Unlike other migraine treatments used in the ED, eptinezumab can rapidly interrupt the migraine process, potentially also preventing migraine from coming back in the short term.
Most patients with a diagnosis of migraine have no access to preventative therapies. This study will be able to provide access to preventative therapy at the earliest stages of a migraine attack. Administering this medication in the ED may stop the attack more effectively compared to current therapies.
This study wants to see if eptinezumab could help stop migraines from coming back after individuals have been treated in the ED. The study will also explore whether eptinezumab could reduce how often individuals with migraine might need to come back to the ED, what other medications they might need alongside eptinezumab, and how they feel overall.

开始日期2024-09-30

申办/合作机构

Healthtech Connex, Inc.

[+3]

NCT05937152 / Recruiting临床2期

CAT-Trial: CGRP Monoclonal Antibody for Treatment of Painful Diabetic Neuropathy: a Double-blind, Randomized, Placebo-controlled, International Multicenter, Phase II Clinical Trial

The main purpose of this study is to compare the change in pain intensity during treatment with a CGRP monoclonal antibody (eptinezumab) compared with placebo treatment in patients with painful diabetic polyneuropathy (DPN).

开始日期2024-06-01

申办/合作机构

Mayo Clinic

NCT06409845 / RecruitingN/AIIT

Effectiveness and Tolerability of Eptinezumab: a Prospective, Multicentric, Cohort Study

The purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of eptinezumab as preventive migraine treatment in a cohort of episodic or chronic migraine patients.

开始日期2024-03-26

申办/合作机构

University of Florence

[+8]

100 项与艾普奈珠单抗相关的临床结果

登录后查看更多信息

100 项与艾普奈珠单抗相关的转化医学

登录后查看更多信息

100 项与艾普奈珠单抗相关的专利（医药）

登录后查看更多信息

167

项与艾普奈珠单抗相关的文献（医药）

2024-04-01·Hospital pharmacy

Anti-CGRP mAbs for the Preventive Treatment of Migraine: An Overview Review and a Cost Saving Analysis in the Global Scenario

Article

作者: Zovi, Andrea ; Sabbatucci, Michela ; Langella, Roberto ; Musazzi, Umberto Maria ; Ferrara, Francesco ; Lasala, Ruggero ; Vitiello, Antonio

Objectives: Migraine is a neurological disease with a high frequency of incidence. The new monoclonal antibodies selective for the calcitonin gene-related peptide and its ligand (anti-CGRP mAbs) have been marketed both in the USA and EU based on the positive efficacy results in the prevention of migraine. This search has been carried out with the aim of collecting real-world evidence on the effectiveness of anti-CGRP mAbs, performing a cost-savings analysis, and comparing performances among anti-CGRP mAbs medicines marketed in the American and European market. Methods: The literature review has been performed in PubMed database on 31 December 2022; the cost of the unitary dose of anti-CGRP mAbs has been extracted consulting an American national database. Results: The results confirm efficacy and good tolerability of anti-CGRP mAbs, determining a difference in the purchase price. In fact, all extracted studies showed a protective risk factor exposure in monthly migraine days reduction for all the anti-CGRP mAbs, whereas the cost analysis showed that using eptinezumab, in a quarter there is a cost saving of at least $425 per patient, compared with the other anti-CGRP mAbs. Conclusions: With equal efficacy and equal safety, anti-CGRP mAbs should be prescribed also regard to the cost established at the negotiation, making sure to guarantee the best treatment to the patients, but at the same time impacting as little as possible to the healthcare services resources.

2024-02-29·Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology

Efficacy and Safety of Anti-CGRP Monoclonal Antibodies in Prevention of Chronic Migraine: A Bayesian Network Meta-analysis

Review

作者: Haridas, Mundot Puliappadamb ; Srinivasan, Anand ; Maiti, Rituparna ; Tripathy, Amruta

Due to the unmet needs in the management of migraine, a primary headache, and disabling disorder, the past decade has focused on developing monoclonal antibodies (mAbs) against the calcitonin-gene-related peptide (CGRP) as migraine prophylactic agents. The objective of the study was to evaluate the efficacy and safety of various anti-CGRP mAbs in the prevention of chronic migraine. Network meta-analysis (NMA) was performed using the Bayesian framework to estimate the efficacy and safety of mAbs after performing a literature search in PubMed, MEDLINE, Cochrane database, and International Clinical Trial Registry Platform (ICTRP). The outcomes calculated were in terms of mean difference (MD) or odds ratio (OR) with a 95% credible interval (95%CrI). Network graphs were constructed and node-split analysis was done to analyze the inconsistency. The NMA included a total of 10 clinical trials. Galacanezumab (120 mg) (MD: -2.7; 95%CrI: -4.8 to -0.83) was found to be better than other mAbs in terms of the difference in mean migraine days (MMD). Fremanezumab quarterly dose administration showed the best response (OR: 2.9; 95%CrI: 1.9 to 4.6) in terms of responder rate. Eptinezumab was found to be safer (OR: 0.88; 95%CrI: 0.61-1.3) as compared to other mAbs in terms of the rate of adverse events. Fremanezumab (quarterly) ranked better in terms of response rate, and eptinezumab was found to be the safest in the prophylactic management of migraine. Galacenequmab was better at reducing MMD. Further studies are needed to evaluate the long-term safety, efficacy, and use of mAbs in migraine patients.

2024-02-01·European journal of neurology

Responder rates with eptinezumab over 24 weeks in patients with prior preventive migraine treatment failures: post hoc analysis of the DELIVER randomized clinical trial

Article

作者: Mitsikostas, Dimos D ; Lipton, Richard B ; Versijpt, Jan ; Ashina, Messoud ; Ettrup, Anders ; Christoffersen, Cecilie Laurberg ; Sperling, Bjørn ; Sacco, Simona ; Ailani, Jessica

Abstract:

Background and purpose:

Eptinezumab reduced monthly migraine days more than placebo in the DELIVER study, a clinical trial with patients with difficult‐to‐treat migraine and prior preventive treatment failures. This post hoc analysis assesses the sustained response to eptinezumab at the population and patient level and evaluates the potential for response in initial non‐responders.

Methods:

Adults with chronic or episodic migraine and two to four prior preventive treatment failures were randomized to eptinezumab 100 mg, 300 mg or placebo every 12 weeks. Primary outcomes in this post hoc analysis are the proportion of patients with ≥30%, ≥50% or ≥75% reduction in monthly migraine days (i.e., migraine responder rates [MRRs]) during weeks 1–12 and weeks 13–24 and across 4‐week intervals. Secondary outcomes are maintenance and shifts in MRRs from weeks 1–12 to weeks 13–24.

Results:

Between weeks 1–12 and 13–24, ≥30% MRRs increased from 65.9% to 70.4% (100 mg) and from 71.0% to 74.5% (300 mg), versus 36.9% to 43.1% (placebo). The ≥50% and ≥75% MRRs were sustained or increased over the 24‐week period. The largest increase in ≥30% MRRs occurred after the second infusion with eptinezumab. The percentage of initial non‐responders (<30% MRRs during weeks 1–12) who experienced response (≥30% MRRs during weeks 13–24) to the second dose was 34.7% (100 mg) and 30.4% (300 mg) with eptinezumab versus 21.1% with placebo.

Conclusion:

Across MRR thresholds, most patients who responded to eptinezumab during weeks 1–12 maintained or improved response during weeks 13–24. More than one‐third of initial non‐responders became responders after their second infusion.

48

项与艾普奈珠单抗相关的新闻（医药）

2024-03-20

·药时代

做了两年多的药企CEO，倦了

2023年2月9日，鲍勃·阿塞尔比（Bob Azelby）黯然离开了工作时长2年半的Eliem Therapeutics。鲍勃作为Eliem的首任CEO，与其同批离开的还有全司55%的员工。Eliem是一家十分年轻的公司，2019年在RA Capital Management、Access Biotechnology 等投资机构的资助下成立并一直处于隐匿模式。直至2023年3月，Eliem凭借一则“我司获得8000万美元融资”的新闻稿，正式对外亮相，那时鲍勃已然是该公司的CEO了。Eliem的定位十分清晰，专注于CNS治疗领域。尽管公司刚刚出道，但旗下已然拥有慢性疼痛治疗药物ETX-810（两项2a期临床进行中）、抗精神类药物ETX-155（即将启动多项2a期临床）两款候选药物。这对刚从Alder BioPharmaceuticals离开的鲍勃而言，可谓是“神仙开局”。不同于众多深耕CNS领域中的学术大佬，鲍勃是商务出生且工作履历颇为曲折。青年时期的鲍勃，先是在安进做了15年商务，后去了Juno Therapeutics做了3年首席商务官，但由于公司被Celgene Corporation收购，再次转战Alder BioPharmaceuticals，而鲍勃也是在这份工作履历中正式涉足CNS治疗领域。鲍勃是2018年加入Alder的，任CEO一职。彼时的Alder作为CNS领域明星企业，被灵北看中后，于2019年以近20亿美元收购，2020年FDA批准首款用于预防成人偏头痛药物eptinezumab（Alder原研）。尽管这段工作经历颇为短暂，但也成就了鲍勃在CNS治疗领域中的管理地位。Eliem的CEO，鲍勃“当仁不让”。时间来到2021年5月，即Eliem“出世”2个月后，公司再获6000万美元B轮融资，同年8月成功IPO，获9200万美元股权融资。鲍勃在2021年半年报中慷慨表示，“对于Eliem，这是激动人心的一年，我们将用这些资金去推动手中这些具有潜力的产品，致力于CNS治疗药物的开发。”然而，就是这般慷慨激昂的言论，2年后的鲍勃怎么也说不出了。在鲍勃任职Eliem CEO的2年时间里，核心管线相继受挫。先是进展最快的ETX-810在用于糖尿病周围神经性疼痛和腰骶神经根疼痛的两项2a试验失败（2022年8月停止开发），后是ETX-155在早期研究中出现CMC问题，多项临床研究被推迟。终于在2023年2月，Eliem宣布暂停ETX-155的开发（已经完成1期临床用于抑郁症研究），为了符合股东最佳利益，反而将研发重心再次转向聚焦临床前产品ETX-123，并裁员55%，这其中也包括鲍勃的离开。所谓“人挪活树挪死”。离开之后的鲍勃，加入了ADC Therapeutics、Cardinal Health等多家药企的董事会，日子要相比在Eliem作全职CEO时，相对安心。而Eliem在2023年7月宣布“计划探索战略代替方案”，并停掉了最后一个项目ETX-123。截止2023年6月30日，该公司拥有未经审计的初步现金、现金等价物及可流通证券投资总额约为 1.026 亿美元。可以说，Eliem正处在破产清算的边缘。直至2024年3月19日，Eliem宣布计划并购一家名为Tango的Biotech，初步估值为2000万美元，交易方式为股价换购。值得一提的是，Tango由RA Capital Management关联基金控制，而RA本身就是Eliem的大股东，此次收购有助于整合内部资源，降低未来发展的风险。当然，这一切，对于鲍勃没有太大关系了。点击这里，观看精彩直播！

临床2期IPO并购抗体药物偶联物临床3期

2024-03-12

·生物制品圈

一文读懂 | GPCR抗体开发的前景和挑战

导读：G 蛋白偶联受体（GPCR, G protein-coupled receptor）是细胞表面的膜蛋白家族，在人体及多种动物体内广泛存在。GPCR 参与多种疾病的发生机制，如癌症、神经疾病、代谢疾病、免疫疾病和炎症等。因此，GPCR是药物开发的重要靶点。然而，由于跨膜蛋白自身的特性，GPCR靶向药物（尤其是抗体）开发的最大挑战在于抗原的可及性，在体外很难获得具有生物活性的全长GPCR蛋白。今天的文章，菌菌总结了GPCR抗体开发的潜力和难点，包括GPCR抗体的应用前景、早期开发流程与面临的技术挑战。我们还汇总了当前的GPCR免疫原类型及优劣势，包括表达目标抗原的全细胞或细胞膜、VLP嵌合抗原、纯化后的抗原、DNA、以及最新技术驱动下的mRNA免疫原。 GPCR是最大的蛋白质超家族之一，由800多个家族成员组成。这类受体的结构特点是具有七个跨膜结构域。GPCR激动剂能够诱导其构象变化，激活其与下游信号蛋白（以异三聚体G蛋白为主）的结合。GPCR家族蛋白作用于多种细胞通路。据早期文献报道，约40%的上市药物通过GPCR介导其效应。 GPCR的化学特性、结构、信号和药理学有助于靶向药物的开发。2012年的诺贝尔化学奖授予了Brian Kobilka和Robert Lefkowitz，以表彰他们关于“G蛋白偶联受体功能方面的重要发现”。根据既往报道，超过200个GPCR靶点在临床前或临床研究中显示出特异性抗体开发的可行性，涵盖多疾病领域，如肿瘤、代谢疾病、炎症、呼吸道疾病、感染性疾病等。目前，FDA已批准3种靶向GPCR或GPCR相关配体的单克隆抗体用于非肿瘤适应症，分别为莫格利珠单抗（mogamulizumab, C-C 趋化因子受体4(CCR4)）、erenumab（抗降钙素基因相关肽(CGRP)1型受体）和eptinezumab（CGRP）。其他在研的GPCR抗体靶点包括但不限于C-C趋化因子受体7 (CCR7)、CCR5、C-X-C基序趋化因子受体2（CXCR2）、CXCR4、C-X3-C 趋化因子受体1（CX3CR1）、补体5a受体（C5aR）、G蛋白偶联受体（GPR20）、GPR56、β1-肾上腺素受体、胃泌素/胆囊收缩素B型受体（CCKBR）、趋化因子样受体1 （CMKLR1）、甲酰基肽受体1（FPR1）、胰高血糖素受体（GCGR）、蛋白酶激活受体4（PAR4）、富含亮氨酸重复单位的G蛋白偶联受体（LGR5）。抗体类药物的早期开发流程一般为抗原选择、抗原制备、动物免疫、抗体筛选和测序，以获得特异性抗体序列，随后进行抗体改造、体外试验、动物试验和临床试验验证。 2.1 GPCR抗原的选择和制备抗原发挥免疫原的作用，刺激宿主动物产生特异性抗体，随后通过一定的筛选手段进行鉴别。抗原的选择和制备是抗体开发的重要环节。目前，GPCR常用的免疫原种类包括：纯化的抗原、全细胞、细胞膜组分、病毒样颗粒（VLP）、合成多肽、DNA和mRNA。GPCR抗原的制备是一大技术难题，不同种类抗原的制备方式、免疫原性和特异性存在很大差异。 2.2 动物免疫与GPCR抗体筛选目标抗原制备完成后，下一步是进行动物免疫。常规单克隆抗体通常选择鼠、兔、羊等作为宿主动物进行抗原免疫；而纳米抗体（也称单域抗体）、重链抗体的筛选以羊驼或鲨鱼为代表。动物免疫的其他关键点包括宿主动物的年龄、抗原用量、注射方式和部位等。随着传统单克隆抗体、双特异性抗体、抗体偶联药物、纳米抗体的发展，抗体筛选技术也趋于成熟，包括杂交瘤技术、B细胞筛选技术、噬菌体展示技术、酵母展示技术等。我们可以通过以上方法得到抗体序列，包括可变区域的互补决定区（CDR）。 GPCR抗体的开发同样面临技术上的挑战，主要在于GPCR特异性抗原或抗原表位的可及性，及其与GPCR生物学的相关性。当前虽存在多种类型的抗原用于抗体的筛选，然而或多或少存在缺陷与不足。全细胞抗原、膜组分和VLP存在其他背景抗原的干扰，免疫原性和特异性差；纯化抗原较难制备；多肽类抗原完整性差；DNA抗原细胞核内递送困难、抗原表达水平低且依赖佐剂。依托mRNA这一近年趋向成熟的技术平台（核苷酸修饰和递送技术等不断优化），能够在目标宿主内表达天然有活性的GPCR蛋白。mRNA作为免疫原的独特优势，有望在GPCR抗体筛选中发挥有效作用，加速GPCR抗体成药的研发进程。参考文献 [1] Hutchings CJ, Koglin M, Olson WC, Marshall FH. Opportunities for therapeutic antibodies directed at G-protein-coupled receptors. Nat Rev Drug Discov. 2017 Sep;16(9):787-810. doi: 10.1038/nrd.2017.91. [2] Gulezian E, Crivello C, Bednenko J, Zafra C, Zhang Y, Colussi P, Hussain S. Membrane protein production and formulation for drug discovery. Trends Pharmacol Sci. 2021 Aug;42(8):657-674. doi: 10.1016/j.tips.2021.05.006. [3] Hutchings CJ. A review of antibody-based therapeutics targeting G protein-coupled receptors: an update. Expert Opin Biol Ther. 2020 Aug;20(8):925-935. doi: 10.1080/14712598.2020.1745770.[4] High P, Carmon KS. G protein-coupled receptor-targeting antibody-drug conjugates: Current status and future directions. Cancer Lett. 2023 Jun 28;564:216191. doi: 10.1016/j.canlet.2023.216191. 内容来源于网络，如有侵权，请联系删除。

信使RNA细胞疗法

2024-03-11

·PRNewswire

American Headache Society Publishes Updated Guidance on Migraine Preventive Therapy

Recommends therapies targeting calcitonin gene-related peptide (CGRP) as a first-line option for migraine prevention MOUNT ROYAL, N.J., March 11, 2024 /PRNewswire/ -- The American Headache Society (AHS) published a consensus position statement today in Headache: The Journal of Head and Face Pain about the first-line role CGRP-targeting therapies should play in the prevention of migraine. Specifically, the AHS calls for CGRP-targeting therapies to be considered as a first-line approach for migraine prevention, along with previous first-line treatments, without a requirement for prior failure of other classes of migraine preventive treatment. The goal of preventive treatment is to reduce the frequency, intensity, duration, and disability associated with migraine attacks. AHS, the leading medical and scientific organization for healthcare professionals in migraine and other headache disorders, estimates that preventive therapy is indicated for approximately 40% of people with migraine, and many are unable to use existing first-line preventive migraine medicines due to limited effectiveness and tolerability. After a comprehensive review of clinical trial and real-world experience, the AHS found the evidence supporting the efficacy, tolerability, and safety of CGRP-targeting therapies—such as monoclonal antibodies (erenumab, fremanezumab, galcanezumab, and eptinezumab) and small-molecule CGRP receptor antagonists (rimegepant and atogepant)—for migraine prevention to be substantial in its volume, scope, and quality. "Moving CGRP-targeting therapies to the first line of treatment could have a transformational impact on the prevention of migraine attacks and their associated burdens," said Andrew Charles, MD, FAHS, position statement co-author and president of the American Headache Society. "Elevating CGRP-targeting therapies to the first line should reduce barriers for patients to receive these effective treatments and bring hope to countless people who experience this invisible, yet debilitating disease." The new position statement from the AHS, "Calcitonin gene-related peptide (CGRP)-targeting therapies are a first-line option for the prevention of migraine," provides guidance on how to integrate these treatments into clinical practice. ABOUT MIGRAINE Migraine is the third most common disease in the world. In the United States, an estimated 40 million Americans live with migraine. While migraine symptoms vary from person to person, common symptoms include severe headache; nausea and/or vomiting; increased sensitivity to light, sound, or smells; depressed mood or changes in mood; and yawning, fatigue, and difficulty sleeping. ABOUT THE AMERICAN HEADACHE SOCIETY The American Headache Society strives to improve the lives of people impacted by migraine and other headache disorders. The AHS is a professional society of health care providers dedicated to the study and treatment of headache and face pain. The Society's objective is to promote the exchange of information and ideas concerning the causes and treatments of headache and related painful disorders. Educating physicians, health professionals, and the public while encouraging scientific research are the primary functions of our Society. Learn more at AmericanHeadacheSociety.org. This consensus statement published by the American Headache Society (AHS) is an assessment of current scientific and clinical information that is provided as an educational service. The information should not be considered inclusive of all appropriate treatments. New evidence may develop between the time this statement is submitted and when it is published or read. This statement addresses only the question that is specifically identified. It does not mandate any particular course of medical care and is not intended to substitute for the independent professional judgment of the treating provider. CONTACT Tanya Kiniry [email protected] SOURCE American Headache Society

100 项与艾普奈珠单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	艾普奈珠单抗	L01XC	DB14040

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
偏头痛	美国	Lundbeck Seattle BioPharmaceuticals, Inc.	2020-02-21

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
继发性头痛症	临床3期	中国	H. Lundbeck A/S	2021-02-17
继发性头痛症	临床3期	格鲁吉亚	H. Lundbeck A/S	2021-02-17
继发性头痛症	临床3期	韩国	H. Lundbeck A/S	2021-02-17
继发性头痛症	临床3期	西班牙	H. Lundbeck A/S	2021-02-17
继发性头痛症	临床3期	中国台湾	H. Lundbeck A/S	2021-02-17
丛集性头痛	临床3期	美国	H. Lundbeck A/S	2020-12-23
丛集性头痛	临床3期	日本	H. Lundbeck A/S	2020-12-23
丛集性头痛	临床3期	比利时	H. Lundbeck A/S	2020-12-23
丛集性头痛	临床3期	捷克	H. Lundbeck A/S	2020-12-23
丛集性头痛	临床3期	丹麦	H. Lundbeck A/S	2020-12-23

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05284019 (CTgov)	临床4期	偏头痛	32	Onabotulinumtoxin-A (Onabotulinumtoxin-A)	鏇選觸醖鏇鬱鏇獵廠鹽(範夢蓋鏇鏇餘積範齋範) = 鏇網鹹窪醖壓顧窪窪遞獵鬱衊繭餘製獵鬱範範 (淵壓簾艱選獵構遞襯遞, 製網積憲醖顧構鏇遞製 ~ 願憲衊淵顧鑰繭衊艱鹽) 更多	-	2024-05-29
				Eptinezumab (Eptinezumab)	鏇選觸醖鏇鬱鏇獵廠鹽(範夢蓋鏇鏇餘積範齋範) = 繭壓艱築蓋襯齋顧網鹽獵鬱衊繭餘製獵鬱範範 (淵壓簾艱選獵構遞襯遞, 窪廠夢積餘壓齋夢獵製 ~ 餘積構艱壓衊壓艱鹽齋) 更多
NCT02974153 (PROMISE-2, AAN2023)	临床3期	偏头痛 \| 继发性头痛症	1,072	Eptinezumab 100mg	繭獵網鏇淵醖築構顧夢(廠願膚簾窪窪鏇醖餘蓋) = 鹹簾範製顧繭鬱觸廠積簾壓鬱願衊鬱糧網鏇鬱 (餘選廠遞憲觸鹹窪淵醖 ) 更多	积极	2023-04-25
				Eptinezumab 300mg	繭獵網鏇淵醖築構顧夢(廠願膚簾窪窪鏇醖餘蓋) = 餘選願鑰膚鹹觸窪繭鑰簾壓鬱願衊鬱糧網鏇鬱 (餘選廠遞憲觸鹹窪淵醖 ) 更多
NCT04418765 (DELIVER, AAN2023)	临床3期	偏头痛	890	Eptinezumab 100mg	餘積鬱膚遞鏇齋遞膚衊(夢範憲廠簾衊鬱淵憲夢) = 顧醖鹽淵夢壓餘餘蓋鏇遞窪鹹願積鬱遞鬱範獵 (選簾艱願夢獵齋淵夢膚 )	-	2023-04-25
				Eptinezumab 300mg	餘積鬱膚遞鏇齋遞膚衊(夢範憲廠簾衊鬱淵憲夢) = 衊齋餘鏇淵簾鹽蓋艱鑰遞窪鹹願積鬱遞鬱範獵 (選簾艱願夢獵齋淵夢膚 )
AAN2023	N/A	-	31	Eptinezumab 100mg	淵積醖壓襯廠簾鹽獵餘(糧顧鹹鬱壓淵鬱鹽鏇淵) = 77.4% reported that treatment improved disability/function after 6 months of use 壓遞簾選鹹鑰積選構窪 (鏇繭獵壓窪餘蓋窪襯衊 ) 更多	积极	2023-04-25
NCT02974153 \| NCT02559895 (PROMISE studies, Pubmed)	N/A	偏头痛	-	Eptinezumab 100 mg	餘壓簾觸觸願衊壓廠繭(蓋窪糧鏇簾獵淵鏇觸廠) = 鑰齋鏇鹹醖鑰壓糧鹽窪獵淵襯網餘餘鬱製積繭 (憲獵範淵糧製遞壓糧鬱 )	-	2022-10-25
				Eptinezumab 300 mg	餘壓簾觸觸願衊壓廠繭(蓋窪糧鏇簾獵淵鏇觸廠) = 積鏇壓製窪窪顧壓選憲獵淵襯網餘餘鬱製積繭 (憲獵範淵糧製遞壓糧鬱 )
ANA2022	N/A	偏头痛	-	Eptinezumab 100mg	簾獵遞繭築鑰構鹽廠鏇(鹽構鑰鬱鬱窪憲製簾壓) = 壓構簾醖鏇範糧鬱構鬱觸製鏇遞鏇築夢願糧獵 (鹽繭鹹顧壓鏇衊齋觸壓 )	-	2022-09-14
				Eptinezumab 300mg	簾獵遞繭築鑰構鹽廠鏇(鹽構鑰鬱鬱窪憲製簾壓) = 淵衊遞鏇繭觸繭繭壓憲觸製鏇遞鏇築夢願糧獵 (鹽繭鹹顧壓鏇衊齋觸壓 )
NCT02974153 (PROMISE-2, Pubmed)	临床3期	偏头痛	1,072	Eptinezumab 100mg	餘遞窪範簾蓋襯製選餘(獵廠簾選願鹽夢願廠觸) = 網繭願餘觸顧範鑰積遞簾範網襯網艱艱鹹襯膚 (齋齋夢糧鏇網遞鏇壓壓 )	积极	2022-09-06
				Eptinezumab 300mg	繭襯顧齋鹹觸築築製齋(繭壓鑰鬱簾鹽淵壓積襯) = 鹹醖鏇鑰積餘觸艱鹽餘簾選築築簾餘艱獵醖壓 (範廠蓋蓋簾積獵遞願餘 ) 更多
NCT04152083 (RELIEF, Pubmed)	临床3期	偏头痛	485	Eptinezumab 100 mg	構積鏇醖壓鑰製願廠構(觸艱壓鏇窪襯願範遞觸) = 遞壓夢窪壓衊願繭醖糧築簾壓顧壓構夢憲簾鑰 (簾衊積糧簾鏇選鏇淵糧 )	积极	2022-07-28
				Placebo	構積鏇醖壓鑰製願廠構(觸艱壓鏇窪襯願範遞觸) = 夢窪壓醖糧製廠夢製齋築簾壓顧壓構夢憲簾鑰 (簾衊積糧簾鏇選鏇淵糧 )
NCT02985398 (PREVAIL, Pubmed)	临床3期	偏头痛	128	Eptinezumab	鏇窪襯獵齋襯網齋網顧(膚鏇繭淵鏇鹹艱糧窪衊) = 醖鑰襯夢壓範獵製獵顧衊廠淵窪襯壓鏇遞蓋淵 (襯遞艱醖膚網壓鑰築憲 ) 更多	-	2022-07-08
NCT04152083 (RELIEF, Pubmed) 人工标引	临床3期	偏头痛	480	eptinezumab	鏇餘鹹壓餘鹹鹹壓觸窪(窪製選網壓艱顧憲鏇築) = 鹽鹹糧淵鏇鹽淵鹽齋獵膚窪顧顧襯餘廠鹹窪廠 (顧醖網衊築鹽鬱醖艱壓 ) 更多	积极	2022-06-03
				Placebo	鏇餘鹹壓餘鹹鹹壓觸窪(窪製選網壓艱顧憲鏇築) = 壓鹽繭築齋鑰襯鹹獵積膚窪顧顧襯餘廠鹹窪廠 (顧醖網衊築鹽鬱醖艱壓 ) 更多